Biologics and Biostimulants in 2025
Are biologics and biostimulants truly delivering on their promise? The truth is— inconsistent ROI continues to limit widespread adoption, even as global sales grow.
Despite $3.1 billion in sales, venture investment in biostimulants fell by 86% in 2024. Why? Because consistency and scalability remain unresolved challenges across the value chain.
What’s holding back adoption?
Rising production and formulation costs
Performance variability across soils, crops, and climates
Limited distribution and cold‑chain logistics
Knowledge and technical‑support gaps
Fragmented regulations across markets
Each factor increases risk, cost, or uncertainty — eroding confidence in long‑term ROI.
Still, progress is being made. New formulation science, shelf‑life technologies, and packaging innovations (like high‑barrier multilayers, MAP, or active antimicrobial coatings) are extending product durability and cutting waste.
Longer shelf lives alone can raise profit potential by over 30% through reduced spoilage and better inventory turnover.
When combined with improved field data, predictive agronomy, and precision farming tools, biologics are moving closer to dependable performance— one innovation at a time.
Sustainable input technologies aren’t a passing phase.
They are the future’s foundation— bridging productivity with ecological balance.
? The best is truly yet to come for biologics, biostimulants, and sustainable crop nutrition.